{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["22(15)"],"submitter":["Krishnan SM"],"pubmed_abstract":["Duchenne muscular dystrophy (DMD) is a severe and progressive muscle wasting disorder, affecting one in 3500 to 5000 boys worldwide. The NO-sGC-cGMP pathway plays an important role in skeletal muscle function, primarily by improving blood flow and oxygen supply to the muscles during exercise. In fact, PDE5 inhibitors have previously been investigated as a potential therapy for DMD, however, a large-scale Phase III clinical trial did not meet its primary endpoint. Since the efficacy of PDE5i is dependent on sufficient endogenous NO production, which might be impaired in DMD, we investigated if NO-independent sGC stimulators, could have therapeutic benefits in a mouse model of DMD. Male mdx/mTRG2 mice aged six weeks were given food supplemented with the sGC stimulator, BAY-747 (150 mg/kg of "],"journal":["International journal of molecular sciences"],"pagination":["8016"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8347633"],"repository":["biostudies-literature"],"pubmed_title":["Assessing the Use of the sGC Stimulator BAY-747, as a Potential Treatment for Duchenne Muscular Dystrophy."],"pmcid":["PMC8347633"],"pubmed_authors":["Seifert R","Mathar I","Vakalopoulos A","Krishnan SM","Huser J","Sandner P","Dietz L","Haning P","Hartmann E","Nordlohne J"],"additional_accession":[]},"is_claimable":false,"name":"Assessing the Use of the sGC Stimulator BAY-747, as a Potential Treatment for Duchenne Muscular Dystrophy.","description":"Duchenne muscular dystrophy (DMD) is a severe and progressive muscle wasting disorder, affecting one in 3500 to 5000 boys worldwide. The NO-sGC-cGMP pathway plays an important role in skeletal muscle function, primarily by improving blood flow and oxygen supply to the muscles during exercise. In fact, PDE5 inhibitors have previously been investigated as a potential therapy for DMD, however, a large-scale Phase III clinical trial did not meet its primary endpoint. Since the efficacy of PDE5i is dependent on sufficient endogenous NO production, which might be impaired in DMD, we investigated if NO-independent sGC stimulators, could have therapeutic benefits in a mouse model of DMD. Male mdx/mTRG2 mice aged six weeks were given food supplemented with the sGC stimulator, BAY-747 (150 mg/kg of ","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Jul","modification":"2025-05-29T20:04:05.805Z","creation":"2025-05-29T20:04:05.805Z"},"accession":"S-EPMC8347633","cross_references":{"pubmed":["34360780"],"doi":["10.3390/ijms22158016"]}}